DK3898638T3 - Krystallinske former af en par4-hæmmer - Google Patents

Krystallinske former af en par4-hæmmer Download PDF

Info

Publication number
DK3898638T3
DK3898638T3 DK19842497.0T DK19842497T DK3898638T3 DK 3898638 T3 DK3898638 T3 DK 3898638T3 DK 19842497 T DK19842497 T DK 19842497T DK 3898638 T3 DK3898638 T3 DK 3898638T3
Authority
DK
Denmark
Prior art keywords
crystalline forms
par4 inhibitor
par4
inhibitor
crystalline
Prior art date
Application number
DK19842497.0T
Other languages
English (en)
Inventor
Roxana F Schlam
Nicolas Cuniere
Victoria A Mbachu
Zhongping Shi
Petinka I Vlahova
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69187955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3898638(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3898638T3 publication Critical patent/DK3898638T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK19842497.0T 2018-12-21 2019-12-20 Krystallinske former af en par4-hæmmer DK3898638T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862783223P 2018-12-21 2018-12-21
PCT/US2019/067717 WO2020132381A1 (en) 2018-12-21 2019-12-20 Crystalline forms of a par4 inhibitor

Publications (1)

Publication Number Publication Date
DK3898638T3 true DK3898638T3 (da) 2023-11-20

Family

ID=69187955

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19842497.0T DK3898638T3 (da) 2018-12-21 2019-12-20 Krystallinske former af en par4-hæmmer

Country Status (30)

Country Link
US (2) US12129264B2 (da)
EP (1) EP3898638B1 (da)
JP (1) JP7473554B2 (da)
KR (1) KR20210109559A (da)
CN (3) CN121021534A (da)
AU (2) AU2019403348B2 (da)
BR (1) BR112021011688A2 (da)
CA (1) CA3124100A1 (da)
CL (1) CL2021001590A1 (da)
CO (1) CO2021008043A2 (da)
DK (1) DK3898638T3 (da)
EA (1) EA202191760A1 (da)
ES (1) ES2964404T3 (da)
FI (1) FI3898638T3 (da)
HR (1) HRP20231527T1 (da)
HU (1) HUE064830T2 (da)
IL (2) IL284222B2 (da)
LT (1) LT3898638T (da)
MX (1) MX2021007417A (da)
MY (1) MY206303A (da)
PE (1) PE20211963A1 (da)
PL (1) PL3898638T3 (da)
PT (1) PT3898638T (da)
RS (1) RS64900B1 (da)
SA (1) SA521422311B1 (da)
SG (1) SG11202106561RA (da)
SI (1) SI3898638T1 (da)
SM (1) SMT202300417T1 (da)
WO (1) WO2020132381A1 (da)
ZA (1) ZA202105115B (da)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2841437T (lt) 2012-04-26 2017-09-11 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui

Also Published As

Publication number Publication date
SI3898638T1 (sl) 2023-12-29
JP7473554B2 (ja) 2024-04-23
CO2021008043A2 (es) 2021-06-30
AU2019403348A1 (en) 2021-08-05
CN113227102B (zh) 2025-07-18
AU2019403348B2 (en) 2024-11-28
EP3898638A1 (en) 2021-10-27
HRP20231527T1 (hr) 2024-04-26
IL320212A (en) 2025-06-01
CN121021534A (zh) 2025-11-28
IL284222B2 (en) 2025-09-01
CA3124100A1 (en) 2020-06-25
HUE064830T2 (hu) 2024-04-28
PT3898638T (pt) 2023-11-13
MX2021007417A (es) 2021-08-05
US20250026767A1 (en) 2025-01-23
PE20211963A1 (es) 2021-10-04
MY206303A (en) 2024-12-07
SMT202300417T1 (it) 2024-01-10
EA202191760A1 (ru) 2021-10-07
KR20210109559A (ko) 2021-09-06
PL3898638T3 (pl) 2023-12-04
ES2964404T3 (es) 2024-04-05
JP2022514624A (ja) 2022-02-14
US12129264B2 (en) 2024-10-29
US20220064186A1 (en) 2022-03-03
SA521422311B1 (ar) 2024-04-15
WO2020132381A1 (en) 2020-06-25
BR112021011688A2 (pt) 2021-09-08
LT3898638T (lt) 2023-11-10
AU2025201372A1 (en) 2025-03-20
EP3898638B1 (en) 2023-08-30
CL2021001590A1 (es) 2021-12-03
FI3898638T3 (fi) 2023-11-15
CN113227102A (zh) 2021-08-06
IL284222B1 (en) 2025-05-01
SG11202106561RA (en) 2021-07-29
ZA202105115B (en) 2024-02-28
CN121021533A (zh) 2025-11-28
RS64900B1 (sr) 2023-12-29
IL284222A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
DK3810581T3 (da) Krystalmodifikationer af odevixibat
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
IL284226A (en) Novel polymorphic forms of a tgfb inhibitor
IL286218A (en) Solid state forms of ripretinib
DK3972960T3 (da) Krystallinske former af en btk-hæmmer
EP4007756C0 (en) KIF18A INHIBITORS
HUE057852T2 (hu) MCL-1 inhibítorok
DK3472157T3 (da) Krystallinske faste former af en bet-inhibitor
IL277778B (en) Bcl6 inhibitors
DK3541807T3 (da) Krystallinsk form af en magl-inhibitor
DK3830085T3 (da) Deutereret derivat af lanifibranor
DK3894012T3 (da) Krystallinske former og saltformer af en kinasehæmmer
DK3759745T3 (da) Dannelse af piezoelektriske anordninger
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
DK3844162T3 (da) Hæmmere af alfa-v-beta6-integrin
EP4003986A4 (en) Inhibitor compounds
DK3580197T3 (da) Oprensning af pleuromutilin
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
EP3976797A4 (en) ANTI-CRISPR INHIBITORS
DK3826983T3 (da) Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere
DK3749673T3 (da) Krystallinsk form af bictegravir-natrium
DK3630725T3 (da) Krystallinsk form af n-butyldeoxygalactonojirimycin
DK3847175T3 (da) Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor
EP3812456A4 (en) Growth inhibitor
DK3713513T3 (da) Fremgangsmåde til fremstilling af en protesedel